
Peptides
Hilma BiocareBuy with consultation
Retatrutide
NEWIn stock
Limited stock
€80
Hilma BiocareConcentration: 10mg (10000 mcg)
Volume: 10mg(1 vial)
Description
Retatrutide (LY-3437943) is an investigational drug developed for the treatment of obesity and type 2 diabetes. It acts as a triple receptor agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). Structurally, it is a 39-amino acid peptide engineered on a GIP backbone, which enables its multi-receptor activity. Additionally, it is resistant to degradation by the DPP-4 enzyme, which normally breaks down GLP-1 and GIP.
Indications
Retatrutide is intended for improving glycemic control in patients with type 2 diabetes...
